The global dyslipidemia drugs market is anticipated to stagnate at a CAGR of -10.3% in between the forecast period of 2015 to 2023. The market was worth US$17.85 billion in 2014 and the negative CAGR will lead the demand to shrink to US$6.88 billion by 2023 end.The stagnating demand for dyslipidemia drugs across the globe is attributed to the patent expiry for some blockbuster drugs along with the rising availability of generic drugs.
The majority of shares of the global dyslipidemia drugs market is concentrated among a handful of companies. The top five companies account for the combined share of 74.4% in 2014, finds Transparency Market Research. These players are Abbott Laboratories, Daiichi Sankyo Company, Ltd., Pfizer, Inc., Merck & Co., Inc., and AstraZeneca plc. TMR observes that the leading players exercise a substantial clout in the global market on account of the exclusive rights they hold over blockbuster drugs for managing dyslipidemia. They are also pouring in sizeable money in research and development activities, which is helping them retain their lead.
Request A Sample-
The various types of dyslipidemia drugs are statins, bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacins, combination drugs, and cholesterol absorption inhibitors. Of these, the segment of fibrates and omega-3 fatty acid derivatives leads the pack and will decline at the lowest rate of 1.6% during the forecast period. The substantial number of government approvals for this class of drug is boosting the market.